In the classrooms of Normandy, France, a critical public health shift is taking place. On Thursday, April 9, 2026, students at the collège de Merville-Franceville in Calvados participated in a vaccination drive targeting the Human Papillomavirus (HPV), a move that underscores a growing medical consensus: protecting the next generation from cancer requires a gender-neutral approach.
The initiative is part of a broader effort to combat a silent but pervasive threat. In France, approximately 6,300 cancers are linked to HPV every year, making the virus a primary target for national health authorities according to regional health reports. By bringing free vaccinations directly into middle schools, health officials are attempting to close the gap in immunization rates and dismantle the misconception that HPV is exclusively a “women’s health” issue.
As a physician and journalist, I have seen how the stigma surrounding sexually transmitted infections (STIs) often hinders preventative care. The conversations happening in Normandy schools reflect this struggle; some students expressed confusion during the drive, with some describing the virus as “the butterfly virus” or admitting they had no idea what it was. However, the medical reality is clear: HPV is the most common sexually transmitted infection globally, and its impact is not limited by gender.
Understanding the HPV Threat: Beyond the Basics
The Human Papillomavirus (HPV) belongs to the papillomaviridae family. It’s a highly contagious virus transmitted through simple genital contact, most frequently during sexual intercourse, regardless of whether penetration occurs. Because the infection is often silent—meaning it produces no immediate symptoms—many individuals are unaware they are carrying the virus until it causes significant health complications years later.
Medical researchers have identified roughly 200 types of HPV. Even as most of these infections are harmless and clear on their own—the Agence Régionale de Santé (ARS) de Normandie notes that 90% of infections resolve spontaneously within two years—a small subset is far more dangerous. Specifically, 12 types of HPV are classified as high-risk or potentially oncogenic, meaning they have the capacity to trigger the development of various cancers as detailed in health surveillance data.
While cervical cancer is the most well-known result of high-risk HPV, the virus can also lead to cancers of the throat, anus, and penis. This is precisely why the current campaigns emphasize that “these viruses affect boys as much as girls.” By vaccinating both genders, health authorities aim to create a “herd immunity” effect that reduces the overall circulation of the virus in the population.
The Normandy Strategy: A National Blueprint
The current vaccination drives in Normandy are not isolated events but part of a structured national strategy. A national campaign to administer HPV vaccines within the school environment was officially implemented starting in the 2023 school year per the ARS Normandie. This school-based model is designed to remove barriers to access, such as the require for parents to schedule separate medical appointments or navigate the costs of the vaccine.
The collaboration involves the ARS, the Academy of Normandy, and various healthcare partners to ensure that the vaccination process is seamless and integrated into the students’ daily environment. For the HPV vaccine specifically, the recommended protocol involves two doses administered to adolescents between the ages of 11 and 14.
This window of adolescence is critical. Vaccinating children before they are exposed to the virus provides the highest level of protection. By normalizing the vaccine in middle school, the program helps strip away the stigma associated with STIs, framing the shot as a standard preventative measure against cancer rather than a commentary on sexual activity.
A Comprehensive Approach to Adolescent Health
While HPV is a primary focus, health officials are using these school campaigns as an opportunity to conduct a total review of adolescent immunization records. The adolescent years represent a vital “catch-up” period for several essential vaccines.
According to the ARS Normandie, there are three primary vaccinations recommended for this age group:
- HPV Vaccination: Two doses between 11 and 14 years of age.
- Meningococcal ACWY: A single dose recommended between 11 and 14 years. Notably, the national campaign expanded to include this vaccine in September 2025 to protect against bacterial meningitis.
- DTPc (Diphtheria, Tetanus, Polio, and Pertussis): A booster shot is recommended for all adolescents between the ages of 11 and 13.
school health screenings allow providers to identify students who missed early childhood vaccinations. This includes the MMR (Measles, Mumps, Rubella) vaccine, which requires two doses for full protection, and the Hepatitis B vaccine, for which catch-up doses are possible up to the age of 15. Medical guidelines confirm that these different vaccines can be administered during a single session without compromising their efficacy or increasing risk to the patient.
Quick Reference: Adolescent Vaccination Schedule
| Vaccine | Recommended Age | Dosage/Requirement |
|---|---|---|
| HPV (Human Papillomavirus) | 11–14 years | 2 doses |
| Meningococcal ACWY | 11–14 years | 1 dose |
| DTPc (Diphtheria, Tetanus, Polio, Pertussis) | 11–13 years | 1 booster |
| Hepatitis B | Up to 15 years | 2–3 doses (catch-up) |
| MMR (Measles, Mumps, Rubella) | Lifelong catch-up | 2 doses (3 if 1st dose was before 12 months) |
Why Gender-Neutral Vaccination Matters
For years, HPV vaccination was viewed primarily as a tool for preventing cervical cancer, leading to campaigns that targeted girls almost exclusively. However, the medical community has evolved to recognize that boys are not only susceptible to HPV-related cancers but are also primary vectors for the transmission of the virus.
When boys are vaccinated, the prevalence of the virus drops across the entire community. This provides an essential layer of protection for those who cannot be vaccinated or for whom the vaccine was not effective. By framing the HPV vaccine as a general cancer-prevention tool—comparable to the DTPc booster—health officials in Normandy are shifting the narrative from one of “risk behavior” to one of “preventative health.”
The success of these programs depends heavily on education. As seen in the Merville-Franceville drive, there is still a significant knowledge gap among students. Bridging this gap through school-led education ensures that adolescents understand that they are not just receiving a shot, but are actively reducing their lifetime risk of developing oncogenic infections.
As these national campaigns continue to roll out across France, the focus remains on maximizing coverage through accessibility and education. The integration of the meningococcal ACWY vaccine as of late 2025 further demonstrates a commitment to a holistic approach to adolescent wellness.
The next phase of these health initiatives will involve ongoing monitoring of vaccination rates across different regions to ensure equitable access to these life-saving preventatives. Parents and guardians are encouraged to consult their local health authorities or school nurses to verify their children’s immunization status.
Do you believe school-based vaccination drives are the most effective way to increase immunization rates? Share your thoughts in the comments below or share this article with other parents and educators.
Worth a look